DK2820016T3 - N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt - Google Patents
N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsaltInfo
- Publication number
- DK2820016T3 DK2820016T3 DK13708603.9T DK13708603T DK2820016T3 DK 2820016 T3 DK2820016 T3 DK 2820016T3 DK 13708603 T DK13708603 T DK 13708603T DK 2820016 T3 DK2820016 T3 DK 2820016T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyridin
- difluorphenyl
- cyclohepta
- imidazo
- piperidin
- Prior art date
Links
- -1 2,3-DIFLUORPHENYL Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261603598P | 2012-02-27 | 2012-02-27 | |
| PCT/US2013/027648 WO2013130402A1 (en) | 2012-02-27 | 2013-02-25 | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorophenyl) -6, 7, 8, 9 - tetrahydro - 5h - cyclohepta [b] pyridin-9 -yl- 4 - (2 - oxo-2, 3 - dihydro - 1h- imidazo [4, 5 -b] pyridin - 1 - yl) piperidine - 1 - carboxylate, hemisulfate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2820016T3 true DK2820016T3 (da) | 2017-11-13 |
Family
ID=47844498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13708603.9T DK2820016T3 (da) | 2012-02-27 | 2013-02-25 | N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt |
| DK17180587.2T DK3254681T3 (da) | 2012-02-27 | 2013-02-25 | N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17180587.2T DK3254681T3 (da) | 2012-02-27 | 2013-02-25 | N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US8759372B2 (https=) |
| EP (2) | EP3254681B1 (https=) |
| JP (2) | JP6208154B2 (https=) |
| KR (2) | KR102220969B1 (https=) |
| CN (1) | CN104136437B (https=) |
| AU (1) | AU2013226361B2 (https=) |
| BR (1) | BR112014021032B1 (https=) |
| CA (1) | CA2865585C (https=) |
| CY (2) | CY1119448T1 (https=) |
| DK (2) | DK2820016T3 (https=) |
| EA (1) | EA025358B1 (https=) |
| ES (2) | ES2746031T3 (https=) |
| HK (1) | HK1248111B (https=) |
| HR (2) | HRP20171620T1 (https=) |
| HU (2) | HUE047050T2 (https=) |
| IL (1) | IL234272B (https=) |
| LT (2) | LT3254681T (https=) |
| MX (1) | MX352171B (https=) |
| NO (1) | NO2935439T3 (https=) |
| PL (2) | PL3254681T3 (https=) |
| PT (2) | PT3254681T (https=) |
| RS (2) | RS59295B1 (https=) |
| SG (1) | SG11201404834XA (https=) |
| SI (2) | SI2820016T1 (https=) |
| SM (1) | SMT201700489T1 (https=) |
| WO (1) | WO2013130402A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101855242B1 (ko) | 2012-01-26 | 2018-05-09 | 크리스토퍼 제이. 소레스 | 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 |
| HUE047050T2 (hu) * | 2012-02-27 | 2020-04-28 | Bristol Myers Squibb Co | N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| CA3182565A1 (en) | 2015-03-06 | 2016-09-15 | Atea Pharmaceuticals, Inc. | .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment |
| CA3035561A1 (en) * | 2016-09-02 | 2018-03-08 | Christopher J. Soares | Use of cgrp receptor antagonists in neuroprotection and neurological disorders |
| WO2018048937A1 (en) | 2016-09-07 | 2018-03-15 | Atea Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment |
| IL288737B (en) * | 2017-02-01 | 2022-09-01 | Atea Pharmaceuticals Inc | Hemisulfate nucleotide salt for treatment of hepatitis c virus |
| MX2020009856A (es) * | 2018-03-25 | 2020-10-08 | Biohaven Pharm Holding Co Ltd | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). |
| EP3773753A4 (en) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS |
| MX2021008191A (es) * | 2019-01-20 | 2021-08-11 | Biohaven Pharm Holding Co Ltd | Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña. |
| US12521389B2 (en) * | 2019-06-14 | 2026-01-13 | The Regents Of The University Of California | Therapeutic approach to lung disease |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| JP2024509165A (ja) | 2021-03-02 | 2024-02-29 | シージーアールピー ダイアグノスティクス ゲーエムベーハー | 片頭痛の治療及び／又は発生の低減 |
| IL308921A (en) | 2021-06-17 | 2024-01-01 | Atea Pharmaceuticals Inc | Combination anti-HCV therapy is beneficial |
| US20250109188A1 (en) | 2021-08-24 | 2025-04-03 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
| WO2023034466A1 (en) * | 2021-09-02 | 2023-03-09 | Pfizer Ireland Pharmaceuticals | Cgrp antagonists for treating psoriasis |
| CN115850266A (zh) * | 2021-09-26 | 2023-03-28 | 奥锐特药业(天津)有限公司 | 瑞美吉泮新晶型及其制备方法 |
| CN116554164B (zh) * | 2022-01-27 | 2025-10-03 | 奥锐特药业(天津)有限公司 | 一种瑞美吉泮的制备方法 |
| WO2023175632A1 (en) * | 2022-03-17 | 2023-09-21 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof |
| WO2024180562A1 (en) * | 2023-03-02 | 2024-09-06 | Natco Pharma Limited | A process for the preparation of pure crystalline rimegepant and its salts thereof |
| WO2025193980A2 (en) * | 2024-03-13 | 2025-09-18 | CNS Biosciences, Inc. | Method of treating neuropathic pain using an anti-cgrp inhibitor |
| WO2026074002A1 (en) | 2024-10-02 | 2026-04-09 | Krka, D.D., Novo Mesto | Crystalline salts of rimegepant |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA24500A1 (fr) * | 1997-03-21 | 1998-10-01 | Lg Life Sciences Ltd | Derive du sel d'acide carboxylique de naphthyridine . |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| US7855294B2 (en) | 2004-03-05 | 2010-12-21 | Banyu Pharmaceutical Co., Ltd. | Cycloalkanopyridine derivative |
| BRPI0517418A (pt) | 2004-10-13 | 2008-10-07 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça |
| DE602005027230D1 (de) | 2004-10-22 | 2011-05-12 | Merck Sharp & Dohme | Cgrp-rezeptorantagonisten |
| JP2009533438A (ja) | 2006-04-10 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | ピリジン複素環ｃｇｒｐアンタゴニスト中間体の製造方法 |
| DE102006017827A1 (de) * | 2006-04-13 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue kristalline Verbindungen |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
| US8748429B2 (en) | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| HUE047050T2 (hu) * | 2012-02-27 | 2020-04-28 | Bristol Myers Squibb Co | N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B]piridin-9 -yl-4-(2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-il)piperidin-1-karboxilát só |
-
2013
- 2013-02-25 HU HUE17180587A patent/HUE047050T2/hu unknown
- 2013-02-25 SI SI201330759T patent/SI2820016T1/sl unknown
- 2013-02-25 WO PCT/US2013/027648 patent/WO2013130402A1/en not_active Ceased
- 2013-02-25 US US13/775,528 patent/US8759372B2/en active Active
- 2013-02-25 LT LTEP17180587.2T patent/LT3254681T/lt unknown
- 2013-02-25 SM SM20170489T patent/SMT201700489T1/it unknown
- 2013-02-25 RS RSP20191191 patent/RS59295B1/sr unknown
- 2013-02-25 ES ES17180587T patent/ES2746031T3/es active Active
- 2013-02-25 SG SG11201404834XA patent/SG11201404834XA/en unknown
- 2013-02-25 EA EA201491585A patent/EA025358B1/ru not_active IP Right Cessation
- 2013-02-25 SI SI201331560T patent/SI3254681T1/sl unknown
- 2013-02-25 EP EP17180587.2A patent/EP3254681B1/en active Active
- 2013-02-25 PL PL17180587T patent/PL3254681T3/pl unknown
- 2013-02-25 DK DK13708603.9T patent/DK2820016T3/da active
- 2013-02-25 PT PT171805872T patent/PT3254681T/pt unknown
- 2013-02-25 BR BR112014021032-2A patent/BR112014021032B1/pt active IP Right Grant
- 2013-02-25 JP JP2014558927A patent/JP6208154B2/ja active Active
- 2013-02-25 KR KR1020207003401A patent/KR102220969B1/ko active Active
- 2013-02-25 HR HRP20171620TT patent/HRP20171620T1/hr unknown
- 2013-02-25 LT LTEP13708603.9T patent/LT2820016T/lt unknown
- 2013-02-25 AU AU2013226361A patent/AU2013226361B2/en active Active
- 2013-02-25 RS RS20171092A patent/RS56556B1/sr unknown
- 2013-02-25 PT PT137086039T patent/PT2820016T/pt unknown
- 2013-02-25 CN CN201380011305.6A patent/CN104136437B/zh active Active
- 2013-02-25 EP EP13708603.9A patent/EP2820016B1/en active Active
- 2013-02-25 HU HUE13708603A patent/HUE034936T2/hu unknown
- 2013-02-25 MX MX2014009544A patent/MX352171B/es active IP Right Grant
- 2013-02-25 PL PL13708603T patent/PL2820016T3/pl unknown
- 2013-02-25 CA CA2865585A patent/CA2865585C/en active Active
- 2013-02-25 DK DK17180587.2T patent/DK3254681T3/da active
- 2013-02-25 ES ES13708603.9T patent/ES2642737T3/es active Active
- 2013-02-25 KR KR1020147023856A patent/KR102076118B1/ko active Active
- 2013-12-10 NO NO13811338A patent/NO2935439T3/no unknown
-
2014
- 2014-08-24 IL IL234272A patent/IL234272B/en active IP Right Grant
-
2017
- 2017-09-06 JP JP2017171358A patent/JP6476253B2/ja active Active
- 2017-10-10 CY CY20171101052T patent/CY1119448T1/el unknown
-
2018
- 2018-06-12 HK HK18107632.9A patent/HK1248111B/en unknown
-
2019
- 2019-09-11 CY CY20191100951T patent/CY1122121T1/el unknown
- 2019-09-16 HR HRP20191655 patent/HRP20191655T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2820016T3 (da) | N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylat, hemisulfatsalt | |
| IL257886B (en) | History of imidazo[5,4-c]quinoline and imidazo[5,4-c][5,1]naphthyridine as lrrk2 inhibitors | |
| HUE046216T2 (hu) | 1H-pirazolo [3,4-b]piridin-származékok és terápiás alkalmazásuk | |
| PL2807165T3 (pl) | Pochodne pirymido[4,5-b]indolu i ich zastosowanie do namnażania hematopoetycznych komórek macierzystych | |
| IL240397A0 (en) | Forms of methyl {6,4-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [[b-4,3-pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | |
| IL227496B (en) | Pyrazolo[4,3–b]pyridines are converted as drugs | |
| BR112012029437A2 (pt) | derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk | |
| SG11201506813QA (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
| BR112013014854A2 (pt) | compostos de n-(1h-indazol-4-il)midazo [1,2-a] piridina-3-carboxamida substituídos como inibidores de tirosina quinase de receptor tipo iii | |
| IL224903A (en) | Imidzo [c – 5,4] quinolines as DNA inhibitors | |
| CO7000778A2 (es) | Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico | |
| ZA201405070B (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors | |
| ZA201306542B (en) | 7-azaindole derivatives | |
| DK2970260T3 (da) | Imidazo-[4,5-c]pyridin- og pyrrolo-[2,3-c]pyridinderivater som ssao-inhibitorer | |
| DK3478681T3 (da) | 1h-pyrazolo[4,3-b]pyridiner som pde1-inhibitorer | |
| BR112013022948A2 (pt) | derivados de pirido [2,3 - b] pirazina e seus usos terapêuticos | |
| DK3177627T3 (da) | Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet | |
| PT3296299T (pt) | Forma cristalina de 3-etil-4-{3-isopropil-4-(4-(1-metil-1hpirazol- 4-il)-1h-imidazol-1-il)-1h-pirazolo[3,4-b]piridin- 1-il}benzamida | |
| IL241808B (en) | History of n-(2, 3-dihydro-1h-pyrrolo [3,2-b] pyridine-5-yl)-4-quinazolinamine and n-(2, 3-dihydro-1h-indole-5-yl} – 4-quinazolinamine as perk inhibitors | |
| CO7020916A2 (es) | Utilizacion en terapeutica de derivados de imidazopiridina | |
| BR112013013282A2 (pt) | compostos de oxazolo[5,4-b]piridin-5-ila | |
| TH1501001335A (th) | กระบวนการที่ปรับปรุงแล้วสำหรับการเตรียมของ 2-อะมิโน-5,8-ไดเมธอกซิ[1,2,4]ไทรอะโซโล[1,5-c]ไพริมิดีนจาก 4-อะมิโน-2,5-ไดเมธอกซิไพริมิดีน |